Stemline Therapeutic (STML) 8.03 $STML Stemline
Post# of 273258
Posted On: 09/03/2016 1:23:14 AM
Stemline Therapeutic (STML) 8.03 $STML
Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401
GlobeNewswire - Tue Aug 23, 6:30AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
STML: 8.03 (-0.12)
Stemline Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Thu Aug 11, 6:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 2016 Wedbush PacGrow Healthcare conference on Tuesday, August 16, 2016 at 3:40 PM ET. The conference will be held at the Le Parker Meridien in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 8.03 (-0.12)
Stemline Therapeutics Reports Second Quarter 2016 Financial Results and Highlights Recent Clinical Progress
GlobeNewswire - Thu Aug 04, 6:58AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended June 30, 2016. Clinical highlights and milestones include:
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at the EHA Meeting this Weekend
GlobeNewswire - Fri Jun 10, 10:45AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be the subject of an oral presentation this weekend at the 21 Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark.
STML: 8.03 (-0.12)
Stemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference; Will Feature Highlights from this Past Weekend's Oral Presentation of SL-401 Phase 2 Results in BPDCN at ASCO
GlobeNewswire - Mon Jun 06, 6:30AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 10:00 AM ET. During the presentation, Dr. Bergstein will discuss the SL-401 Phase 2 blastic plasmacytoid dendritic cell neoplasm (BPDCN) data presented on June 4 at the 2016 ASCO conference. He will also review next steps for the SL-401 program as well as provide updates on the company's overall pipeline. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds
GlobeNewswire - Sat Jun 04, 6:07PM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The Phase 2 trial results were delivered today by Naveen Pemmaraju, M.D. from the University of Texas MD Anderson Cancer Center, via an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow
GlobeNewswire - Fri Jun 03, 6:06AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be the subject of an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago, IL. The presentation will take place tomorrow, Saturday, June 4, at 5 PM CT.
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Selected for Oral Presentations at the Upcoming ASCO and EHA Meetings
GlobeNewswire - Thu May 19, 6:30AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) was selected for oral presentations at both the upcoming American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago, IL and the 21 Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. The full abstracts are now available on the respective conference websites.
STML: 8.03 (-0.12)
Stemline Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 7:33AM CDT
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Monday reported a loss of $9 million in its first quarter.
STML: 8.03 (-0.12)
Stemline Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 7:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended March 31, 2016.
STML: 8.03 (-0.12)
Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial
GlobeNewswire - Tue May 03, 7:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that it has completed the initial dosing cohort in its SL-801 Phase 1 advanced solid tumor trial. The second cohort is currently open. SL-801 is a novel, oral, small molecule that reversibly inhibits the XPO1 (Exportin-1) nuclear transport protein, a clinically validated target active in a wide variety of cancer types.
STML: 8.03 (-0.12)
Stemline Therapeutics Announces Oral Presentation of SL-401 Phase 2 BPDCN Data at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:01AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data update was selected for oral presentation on June 4, 2016 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
STML: 8.03 (-0.12)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.74 (+0.06), DRNA: 3.14 (+0.01), INCY: 82.02 (+1.21), LLY: 76.85 (-0.38), STML: 8.03 (-0.12), SNTA: 0.34 (+0.07), ANTH: 2.93 (+0.02), EXEL: 11.54 (+0.19)
Stemline Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 04, 9:59AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 4:00 PM ET. The conference is being held at the Waldorf Astoria Hotel in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 8.03 (-0.12)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 169.77 (-0.36), ATRA: 19.70 (-0.15), STML: 8.03 (-0.12), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.06), SNDX: 14.01 (+0.07), BLCM: 17.24 (-0.23), BPTH: 1.55 (-0.03), TEVA: 51.22 (+0.32), AGIO: 36.35 (-0.39), XLRN: 30.84 (+0.59), ARRY: 3.50 (-0.02)
Global High-Grade Glioma Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/lr2n9x/highgrade_glioma) has announced the addition of the "High-Grade Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - High-Grade Glioma Overview - Therapeutics Development - Pipeline Products for High-Grade Glioma - Overview - Pipeline Products for High-Grade Glioma - Comparative Analysis - High-Grade Glioma - Therapeutics under Development by Companies - High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes - High-Grade Glioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - High-Grade Glioma - Products under Development by Companies - High-Grade Glioma - Products under Investigation by Universities/Institutes - High-Grade Glioma - Companies Involved in Therapeutics Development - AngioChem Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - Boehringer Ingelheim GmbH - Cavion LLC - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Nektar Therapeutics - Novartis AG - Oncolytics Biotech Inc. - Sanofi - Stemline Therapeutics, Inc. - Targepeutics, Inc. - Tocagen Inc. - Virttu Biologics Limited For more information visit http://www.researchandmarkets.com/research/lr...ade_glioma
MACK: 4.53 (-0.06), ONCY: 0.33 (-0.02), STML: 8.03 (-0.12), NKTR: 18.45 (+0.34), NVS: 79.38 (+1.11)
Stemline Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 05, 7:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 11:30 AM PT (2:30 PM ET) at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
JPM: 67.49 (+0.28), STML: 8.03 (-0.12)
Global Stemline Therapeutics Inc Product Pipeline Review 2015
M2 - Tue Dec 29, 3:01AM CST
AcuteMarketReports.com has announced the addition of "Global Stemline Therapeutics Inc Product Pipeline Review 2015 "Market Research Report to their Database.
STML: 8.03 (-0.12)
Traders Look to Upside - New Reports on Amkor Technology, A10 Networks, Stemline Therapeutics and Evolent Health
ACCESSWIRE - Thu Dec 24, 6:31AM CST
NEW YORK, NY / ACCESSWIRE / December 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Amkor Technology Inc. (NASDAQ: AMKR), A10 Networks Inc. (NYSE: ATEN), Stemline Therapeutics Inc. (NASDAQ: STML) and Evolent Health Inc. (NYSE: EVH). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AMKR: 9.25 (+0.01), EVH: 24.94 (-0.09), STML: 8.03 (-0.12), ATEN: 10.07 (+0.14)
Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6gxl8w/hypereosinophilic) has announced the addition of the "Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2015" provides an overview of Hypereosinophilic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hypereosinophilic Syndrome. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Novartis AG - GlaxoSmithKline Plc - Stemline Therapeutics, Inc. - Nanotherapeutics, Inc. - Knopp Biosciences LLC - Kirin Holdings Company, Limited - Grindeks - CEPHA s.r.o. - Bristol-Myers Squibb Company - AstraZeneca Plc For more information visit http://www.researchandmarkets.com/research/6g...sinophilic
AZN: 33.31 (+0.71), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), STML: 8.03 (-0.12), NVS: 79.38 (+1.11)
Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401
GlobeNewswire - Tue Aug 23, 6:30AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
STML: 8.03 (-0.12)
Stemline Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Thu Aug 11, 6:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 2016 Wedbush PacGrow Healthcare conference on Tuesday, August 16, 2016 at 3:40 PM ET. The conference will be held at the Le Parker Meridien in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 8.03 (-0.12)
Stemline Therapeutics Reports Second Quarter 2016 Financial Results and Highlights Recent Clinical Progress
GlobeNewswire - Thu Aug 04, 6:58AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended June 30, 2016. Clinical highlights and milestones include:
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at the EHA Meeting this Weekend
GlobeNewswire - Fri Jun 10, 10:45AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be the subject of an oral presentation this weekend at the 21 Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark.
STML: 8.03 (-0.12)
Stemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference; Will Feature Highlights from this Past Weekend's Oral Presentation of SL-401 Phase 2 Results in BPDCN at ASCO
GlobeNewswire - Mon Jun 06, 6:30AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 10:00 AM ET. During the presentation, Dr. Bergstein will discuss the SL-401 Phase 2 blastic plasmacytoid dendritic cell neoplasm (BPDCN) data presented on June 4 at the 2016 ASCO conference. He will also review next steps for the SL-401 program as well as provide updates on the company's overall pipeline. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds
GlobeNewswire - Sat Jun 04, 6:07PM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The Phase 2 trial results were delivered today by Naveen Pemmaraju, M.D. from the University of Texas MD Anderson Cancer Center, via an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow
GlobeNewswire - Fri Jun 03, 6:06AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be the subject of an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago, IL. The presentation will take place tomorrow, Saturday, June 4, at 5 PM CT.
STML: 8.03 (-0.12)
Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Selected for Oral Presentations at the Upcoming ASCO and EHA Meetings
GlobeNewswire - Thu May 19, 6:30AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) was selected for oral presentations at both the upcoming American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago, IL and the 21 Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. The full abstracts are now available on the respective conference websites.
STML: 8.03 (-0.12)
Stemline Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 7:33AM CDT
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Monday reported a loss of $9 million in its first quarter.
STML: 8.03 (-0.12)
Stemline Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 7:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended March 31, 2016.
STML: 8.03 (-0.12)
Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial
GlobeNewswire - Tue May 03, 7:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that it has completed the initial dosing cohort in its SL-801 Phase 1 advanced solid tumor trial. The second cohort is currently open. SL-801 is a novel, oral, small molecule that reversibly inhibits the XPO1 (Exportin-1) nuclear transport protein, a clinically validated target active in a wide variety of cancer types.
STML: 8.03 (-0.12)
Stemline Therapeutics Announces Oral Presentation of SL-401 Phase 2 BPDCN Data at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:01AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data update was selected for oral presentation on June 4, 2016 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
STML: 8.03 (-0.12)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.74 (+0.06), DRNA: 3.14 (+0.01), INCY: 82.02 (+1.21), LLY: 76.85 (-0.38), STML: 8.03 (-0.12), SNTA: 0.34 (+0.07), ANTH: 2.93 (+0.02), EXEL: 11.54 (+0.19)
Stemline Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 04, 9:59AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 4:00 PM ET. The conference is being held at the Waldorf Astoria Hotel in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 8.03 (-0.12)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 169.77 (-0.36), ATRA: 19.70 (-0.15), STML: 8.03 (-0.12), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.06), SNDX: 14.01 (+0.07), BLCM: 17.24 (-0.23), BPTH: 1.55 (-0.03), TEVA: 51.22 (+0.32), AGIO: 36.35 (-0.39), XLRN: 30.84 (+0.59), ARRY: 3.50 (-0.02)
Global High-Grade Glioma Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/lr2n9x/highgrade_glioma) has announced the addition of the "High-Grade Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - High-Grade Glioma Overview - Therapeutics Development - Pipeline Products for High-Grade Glioma - Overview - Pipeline Products for High-Grade Glioma - Comparative Analysis - High-Grade Glioma - Therapeutics under Development by Companies - High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes - High-Grade Glioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - High-Grade Glioma - Products under Development by Companies - High-Grade Glioma - Products under Investigation by Universities/Institutes - High-Grade Glioma - Companies Involved in Therapeutics Development - AngioChem Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - Boehringer Ingelheim GmbH - Cavion LLC - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Nektar Therapeutics - Novartis AG - Oncolytics Biotech Inc. - Sanofi - Stemline Therapeutics, Inc. - Targepeutics, Inc. - Tocagen Inc. - Virttu Biologics Limited For more information visit http://www.researchandmarkets.com/research/lr...ade_glioma
MACK: 4.53 (-0.06), ONCY: 0.33 (-0.02), STML: 8.03 (-0.12), NKTR: 18.45 (+0.34), NVS: 79.38 (+1.11)
Stemline Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 05, 7:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 11:30 AM PT (2:30 PM ET) at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
JPM: 67.49 (+0.28), STML: 8.03 (-0.12)
Global Stemline Therapeutics Inc Product Pipeline Review 2015
M2 - Tue Dec 29, 3:01AM CST
AcuteMarketReports.com has announced the addition of "Global Stemline Therapeutics Inc Product Pipeline Review 2015 "Market Research Report to their Database.
STML: 8.03 (-0.12)
Traders Look to Upside - New Reports on Amkor Technology, A10 Networks, Stemline Therapeutics and Evolent Health
ACCESSWIRE - Thu Dec 24, 6:31AM CST
NEW YORK, NY / ACCESSWIRE / December 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Amkor Technology Inc. (NASDAQ: AMKR), A10 Networks Inc. (NYSE: ATEN), Stemline Therapeutics Inc. (NASDAQ: STML) and Evolent Health Inc. (NYSE: EVH). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AMKR: 9.25 (+0.01), EVH: 24.94 (-0.09), STML: 8.03 (-0.12), ATEN: 10.07 (+0.14)
Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6gxl8w/hypereosinophilic) has announced the addition of the "Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Hypereosinophilic Syndrome Global Clinical Trials Review, H2, 2015" provides an overview of Hypereosinophilic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hypereosinophilic Syndrome. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Novartis AG - GlaxoSmithKline Plc - Stemline Therapeutics, Inc. - Nanotherapeutics, Inc. - Knopp Biosciences LLC - Kirin Holdings Company, Limited - Grindeks - CEPHA s.r.o. - Bristol-Myers Squibb Company - AstraZeneca Plc For more information visit http://www.researchandmarkets.com/research/6g...sinophilic
AZN: 33.31 (+0.71), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), STML: 8.03 (-0.12), NVS: 79.38 (+1.11)
(0)
(0)Scroll down for more posts ▼